Properdin homeostasis requires turnover of the alternative complement pathway

Properdin is a plasma protein and is also released from neutrophil granules following stimulation. At inflammatory sites it can bind bacteria and apoptotic bodies to trigger alternative pathway (AP) activation. Principles governing properdin homeostasis are unknown. We monitored properdin during AP activation and in complement-deficient mice. There was a >90% reduction of properdin in the Crry single-knockout mice (Crry SKO). These membrane complement regulatory protein-deficient mice feature accelerated AP turnover, leading to reduced C3 and fB. Injecting cobra venom factor into wild-type mice activated the AP and led to the consumption of C3, fB, and properdin. However, and unexpectedly, properdin was also deficient in C3−/−, fB−/−, and fD−/− mice. It was present in C1q−/−, C4−/−, and C5−/− mice. These findings implicate AP turnover in the maintenance of basal levels of properdin in the blood. To explore the mechanism, classical pathway-activating immune complexes were infused. Within 10 min, properdin was partially restored in fB−/− but not in C3−/− mice. Markedly reduced properdin in mice deficient in an AP component and its partial restoration by activating C3 suggest a requirement for continuous C3 activation via AP tickover to maintain properdin homeostasis. The mechanism underlying this C3-dependent process was not identified. Engagement of C3a and C5a receptors was ruled out. These findings represent an instructive example of how a positive regulator of an innate immune recognition and effector pathway is controlled. A rationale for such a means to supply properdin for immune reactions is proposed.

[1]  M. Pangburn,et al.  Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement. , 2010, Immunobiology.

[2]  D. Hourcade,et al.  Properdin: emerging roles of a pattern-recognition molecule. , 2010, Annual review of immunology.

[3]  T. Hughes,et al.  Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. , 2009, Molecular immunology.

[4]  L. Trouw,et al.  Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation , 2008 .

[5]  J. Atkinson,et al.  Membrane Protein Crry Maintains Homeostasis of the Complement System1 , 2008, The Journal of Immunology.

[6]  D. Hourcade,et al.  The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis , 2008, Proceedings of the National Academy of Sciences.

[7]  T. Miwa,et al.  Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. , 2008, Blood.

[8]  D. Hourcade,et al.  Properdin Can Initiate Complement Activation by Binding Specific Target Surfaces and Providing a Platform for De Novo Convertase Assembly1 , 2007, The Journal of Immunology.

[9]  K. Yudoh,et al.  Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells. , 2007, Arthritis and rheumatism.

[10]  J. Atkinson,et al.  Targeted and restricted complement activation on acrosome-reacted spermatozoa. , 2005, The Journal of clinical investigation.

[11]  D. Nelson,et al.  Negligible role of antibodies and C5 in pregnancy loss associated exclusively with C3-dependent mechanisms through complement alternative pathway. , 2003, Immunity.

[12]  M. Walport,et al.  Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H , 2002, Nature Genetics.

[13]  J. Volanakis,et al.  Complement activation in factor D-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Zabner,et al.  Expression of the Complement Anaphylatoxin C3a and C5a Receptors on Bronchial Epithelial and Smooth Muscle Cells in Models of Sepsis and Asthma1 , 2001, The Journal of Immunology.

[15]  yang-xin fu,et al.  Impaired Affinity Maturation in Cr2−/− Mice Is Rescued by Adjuvants Without Improvement in Germinal Center Development1 , 2000, The Journal of Immunology.

[16]  B. Palanca,et al.  A critical role for murine complement regulator crry in fetomaternal tolerance. , 2000, Science.

[17]  H. Colten,et al.  Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. , 1999, Immunopharmacology.

[18]  John D Lambris,et al.  Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Pier Paolo Pandolfi,et al.  Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies , 1998, Nature Genetics.

[20]  H. Colten,et al.  Abrogation of the alternative complement pathway by targeted deletion of murine factor B. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  B. Dewald,et al.  Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. , 1997, Journal of immunology.

[22]  R. Karr,et al.  Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Butko,et al.  Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. H. Jansen,et al.  Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. , 1995, The Journal of clinical investigation.

[25]  D. Hourcade,et al.  Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein , 1995, The Journal of experimental medicine.

[26]  H. Ziegler-Heitbrock,et al.  Expression of properdin in human monocytes. , 1994, European journal of biochemistry.

[27]  W. Dippold,et al.  Properdin, a positive regulator of complement activation, is expressed in human T cell lines and peripheral blood T cells. , 1993, Journal of immunology.

[28]  H. Müller-Eberhard,et al.  Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized. , 1989, Molecular immunology.

[29]  Y. Boyd,et al.  Localization of the properdin structural locus to Xp11.23-Xp21.1. , 1989, Genomics.

[30]  T. Farries,et al.  Biosynthesis of properdin. , 1989, Journal of immunology.

[31]  C. López-Larrea,et al.  A familial deficiency of complement factor H , 1987 .

[32]  M. Gubler,et al.  H deficiency in two brothers with atypical dense intramembranous deposit disease. , 1986, Kidney international.

[33]  D. Fearon,et al.  p65: A C3b-binding protein on murine cells that shares antigenic determinants with the human C3b receptor (CR1) and is distinct from murine C3b receptor. , 1985, Journal of immunology.

[34]  R. Thompson,et al.  Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. , 1981, Clinical and experimental immunology.

[35]  J. Atkinson,et al.  Reduced concentrations of the first component of complement in hypogammaglobulinemia: Correction by infusion of γ-globulin , 1978 .

[36]  D. Fearon,et al.  Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase , 1975, The Journal of experimental medicine.

[37]  J. Ziegler,et al.  Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency. , 1975, The Journal of clinical investigation.

[38]  H. Müller-Eberhard,et al.  Metabolism of human C1q. Studies in hypogammaglobulinemia, myeloma, and systemic lupus erythematosus. , 1972, The Journal of clinical investigation.

[39]  F. Rosen,et al.  Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection. , 1970, The Journal of clinical investigation.

[40]  H. J. Muller-Eberhard,et al.  Complement-Immunoglobulin Relation: Deficiency of C'lq Associated with Impaired Immunoglobulin G Synthesis , 1969, Science.

[41]  A. Wardlaw,et al.  The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. , 1954, Science.

[42]  P. Lachmann The amplification loop of the complement pathways. , 2009, Advances in immunology.

[43]  John D Lambris,et al.  DAF/Crry double deficiency in mice exacerbates nephrotoxic serum-induced proteinuria despite markedly reduced systemic complement activity. , 2007, Molecular immunology.

[44]  J. V. van Strijp,et al.  Anaphylatoxins: their role in bacterial infection and inflammation. , 2007, Immunologic research.

[45]  David Garrick,et al.  Repeat-induced gene silencing in mammals , 1998, Nature Genetics.

[46]  J. Atkinson,et al.  Control of the complement system. , 1996, Advances in immunology.

[47]  H. Müller-Eberhard,et al.  Molecular organization and function of the complement system. , 1988, Annual review of biochemistry.

[48]  J. Atkinson,et al.  Reduced concentrations of the first component of complement in hypotammaglobulinemia: correction of infusion of gamma-globulin. , 1978, Clinical immunology and immunopathology.

[49]  Louis Pillemer,et al.  THE PROPERDIN SYSTEM AND IMMUNITY III. THE ZYMOSAN ASSAY OF PROPERDIN , 1956 .